It has been recently shown that ARF deletions frequently occur in Ph+ ALL patients and contribute to resistance to targeted therapy in ALL induced by BCR-ABL1 [16, 41]. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.